SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 12b-25
Commission File Number 1-7090
NOTIFICATION OF LATE FILING
(Check One): Form 10-K Form 11-K Form 20-F XX Form 10-Q Form N-SAR
--
For Period Ended: November 2, 1996
-----------------------
Transition Report on Form 10-K
Transition Report on Form 20-F
Transition Report on Form 11-K
Transition Report on Form 10-Q
Transition Report on Form N-SAR
For Period Ended :
Read attached instruction sheet before preparing form. Please
print or type.
Nothing in this form shall be construed to imply that the
Commission has verified any information contained herein.
If the notification relates to a portion of the filing checked
above, identify the item(s) to which the notification relates: N/A
PART I
REGISTRANT INFORMATION
Full name of registrant: Pharmhouse Corp.
Former name if applicable:
Address of principal executive office (Street and number):
860 Broadway
City, state and zip code: New York, NY 10003
PART II
RULE 12B-25 (b) AND (c)
If the subject report could not be filed without unreasonable
effort or expense and the registrant seeks relief pursuant to Rule
12b-25 (b), the following should be completed.
(Check appropriate box.)
X (a) The reasons described in reasonable detail in Part III of
this form could not be eliminated without unreasonable
effort or expense;
X (b) The subject annual report, semi-annual report, transition
report on Form 10-K. 20-F, 11-K of Form N-SAR. Or portion
there of will be filed on or before the 15th calendar day
following the prescribed due date; of the subject quarterly
report of transition report on Form 10-Q, or portion thereof
will be filed on or before the fifth calendar day following
the prescribed due date; and
(c) The accountant's statement or other exhibit required by Rule
12b-25(c) has been attached if applicable.
PART III
NARRATIVE
State below in reasonable detail the reasons why Form 10-K, 11-K,
20-F, 10-Q, N-SAR or the transition report portion thereof could not
be filed within the prescribed time period. (Attached extra sheets
if needed.)
SEE ATTACHMENT
-------------------------------------------------------------
PART IV
OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to
this notification:
Richard A. Davis, Chief Financial Officer 212-477-9400, ext. 635
-----------------------------------------------------------------
(Name) (Area Code)(Telephone Number)
(2) Have all other periodic reports required under Section 13 or
15(d) of the Securities Exchange Act of 1934 or Section 30 of
the Investment Company Act of 1940 during the preceding 12
months or for such shorter period that the registrant was
required to file such report(s) been filed? If the answer
is no, identify report(s).
X Yes __ No
(3) It is anticipated that any significant change in results of
operations from the corresponding period for the last fiscal
year will be reflected by the earnings statements to be
included in the subject report or portion thereof?
X Yes __ No
If so: attach an explanation of the anticipated change, both
narratively and quantitatively, and, if appropriate, state the
reasons why a reasonable estimate of the results cannot be made.
SEE ATTACHMENT
Pharmhouse Corp.
-----------------------------------------------------------
(Name of Registrant as Specified in Charter)
Has caused this notification to be signed on its behalf by the
undersigned thereunto duly authorized.
Date: December 17, 1996 By:/s/ Richard A. Davis
-----------------------------------------
Richard A. Davis, Chief Financial Officer
Instruction. The form may be signed by an executive officer
of the registrant or by any other duly authorized representative.
The name and title of the person signing the form shall be typed
or printed beneath the signature. If the statement is signed on
behalf of the registrant by an authorized representative (other
than an executive officer), evidence of the representative's
authority to sign on behalf of the registrant shall be filed
with the form.
ATTENTION
Intentional misstatement or omissions of fact constitute Federal
criminal violations (see 18 U.S.C. 1001).
GENERAL INSTRUCTIONS
1. This form is required by Rule 12b-25 of the General Rules
and Regulations under the Securities and Exchange Act of
1934.
2. One signed original and four conformed copies of this
form and amendments thereto must be completed and filed
with the Securities and Exchange Commission, Washington,
DC 20549, in accordance with Rule 0-3 of the General
Rules and Regulations under the Act. The information
contained in or filed with the form will be made a matter
of the public record in the Commission files.
3. A manually signed copy of the form and amendments thereto
shall be filed with each national securities exchange on
which any class of securities of the registrant is
registered.
4. Amendments to the notifications must also be filed on Form
12b-25 but need not restate information that has been
correctly furnished. The form shall be clearly identified
as an amended notification.
5. Electronic Filers. This form shall not be used by
electronic filers unable to timely file a report solely due
to electronic difficulties. Filers unable to submit a
report within the time period prescribed due to
difficulties in electronic filing should comply with either
Rule 201 or Rule 202 of Regulation S-T or apply for an
adjustment in filing date pursuant to Rule 13(b) of
Regulation S-T.
PHARMHOUSE CORP.
FORM 12b-25
ATTACHMENT TO PART III OF FORM 12b-25
Owing to demands upon management's time during fourth quarter of
current fiscal year (which includes Christmas shopping season),
management of Registrant has encountered delays in compiling
and completing information and data required for filing Form
10-Q for third fiscal quarter.
ATTACHMENT TO PART IV OF FORM 12b-25
The Registrant sustained a loss from operations for its fiscal
quarter ended November 2, 1996, but a reasonable estimate of the
results for the most recent fiscal quarter to be reported upon
in the Form 10-Q Report cannot be made as of this date because
certain information and data, which will have a material effect
upon such reported results of operation, is not available as of
this date.
* * * * * * * * *
